Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (871-880 of 1,038) with videos related to

Pageof 104
Sort By:
Journal of the American College of Emergency Physicians Open|June 22, 2026
Alignment of United States Emergency Medicine Programs' Pregnancy, Parental Leave, and Lactation Policies With Recent Consensus RecommendationsLaura G Shepherd, Michelle D Lall, Shivam Champaneria, et al.
Lancet (London, England)|January 11, 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trialArmin Ghobadi, Veronika Bachanova, Krish Patel, et al.
Bone Marrow Transplantation|December 16, 1998
CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignanciesP V O'Donnell, R J Jones, G B Vogelsang, et al.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
ACS Nano|February 21, 2024
Sensing the Spin State of Room-Temperature Switchable Cyanometallate Frameworks with Nitrogen-Vacancy Centers in NanodiamondsBradley T Flinn, Graham A Rance, William J Cull, et al.
American Journal of Hematology|May 26, 2016
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLLIan W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, et al.
Leukemia & Lymphoma|July 16, 2011
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasDouglas E Gladstone, Javier Bolaños-Meade, Carol Ann Huff, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial deposit formation in the aging eyeRichard B Thompson, Valentina Reffatto, Jacob G Bundy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2023
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trialA S Cottereau, L Rebaud, J Trotman, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Pageof 104

Showing results (871-880 of 1,038) with videos related to

Sort By:
Pageof 104
Journal of the American College of Emergency Physicians Open|June 22, 2026
Alignment of United States Emergency Medicine Programs' Pregnancy, Parental Leave, and Lactation Policies With Recent Consensus RecommendationsLaura G Shepherd, Michelle D Lall, Shivam Champaneria, et al.
Lancet (London, England)|January 11, 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trialArmin Ghobadi, Veronika Bachanova, Krish Patel, et al.
Bone Marrow Transplantation|December 16, 1998
CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignanciesP V O'Donnell, R J Jones, G B Vogelsang, et al.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
ACS Nano|February 21, 2024
Sensing the Spin State of Room-Temperature Switchable Cyanometallate Frameworks with Nitrogen-Vacancy Centers in NanodiamondsBradley T Flinn, Graham A Rance, William J Cull, et al.
American Journal of Hematology|May 26, 2016
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLLIan W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, et al.
Leukemia & Lymphoma|July 16, 2011
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasDouglas E Gladstone, Javier Bolaños-Meade, Carol Ann Huff, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial deposit formation in the aging eyeRichard B Thompson, Valentina Reffatto, Jacob G Bundy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2023
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trialA S Cottereau, L Rebaud, J Trotman, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Pageof 104